Noveome Biotherapeutics

Funding and NIH signals

• SEC Form D raise Raised $6.75M in debt securities (Form D filed Aug 27, 2026). SEC Form D 0001478304-26-000003 (Aug 27, 2026)
  Evidence (1 event)

  • Aug 27, 2026 · SEC Form D 0001478304-26-000003
    Name of Issuer: Noveome Biotherapeutics, Inc.; CIK: 1478304; Address: Pittsburgh, PA; Submission type: D; Filing date: 2026-08-27; Industry Group: Biotechnology; Date of First Sale: 2026-08-12; Types of Securities Offered: Debt, Other (Convertible promissory notes); Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 6750503; Federal exemptions: 06b
• NIH award NIH awarded $265K (STTR Phase I 1R41AG099399-01A1, new, notice Sep 7, 2026). NIH RePORTER 1R41AG099399-01A1 (Sep 7, 2026)
  Evidence (1 event)

  • Sep 7, 2026 · NIH RePORTER 1R41AG099399-01A1
    Organization: NOVEOME BIOTHERAPEUTICS, INC.; City/State: PITTSBURGH, PA; Project number: 1R41AG099399-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 265064; Administering IC: National Institute on Aging; Project title: Intranasal ST266 Treatment of the Intracerebroventricular Streptozotocin Rat Model of Cognitive Impairment; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Raises and deals from press releases

• Raise Series E · $51M · announced Apr 23, 2025 Company release ↗
  Source quote

  • Apr 23, 2025 · Company release ↗
    “Noveome Biotherapeutics, Inc. Completes $51 million Series E Financing to Support Clinical Trials in NEC”

Raises announced in these releases: $51M disclosed.

From the company’s own releases; this list is partial. All raises and deals